ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium Cells for the Treatment of Macular Degeneration Phase 1/2 Clinical Trials of RPE Cells for the Treatment of Dry Age-Related Macular Degeneration and Stargardt's Macular Degeneration Show Positive Long Term Safety Results and Signs of Visual Improvement ACT to Host a Conference Call on Wednesday, October 15, 2014 at 4:30 PM Eastern Time. Interested Parties may access the call live by dialing 264-3177 and using Conference ID 18428590 .
http://ift.tt/1r5iIQU
http://ift.tt/1r5iIQU
No comments:
Post a Comment